Dechra Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Dechra Pharmaceuticals generated cash of $63,600,000, which is less than the previous year. Cash used in financing activities reached the amount of $316,500,000 last year. Net change in cash is therefore -$46,500,000.
Cash Flow
| 2010 | 17.32M | -1.71M | -10.82M |
|---|---|---|---|
| 2011 | 16.75M | -36.17M | 18.86M |
| 2012 | 19.24M | -120.34M | 103.70M |
| 2016 | 43.57M | -174.03M | 125.31M |
| 2018 | 64M | -241.7M | 193.8M |
| 2020 | 106.4M | -81.5M | 118.9M |
| 2021 | 89.1M | -136.1M | -55.1M |
| 2023 | 63.6M | -426.2M | 316.5M |
DPH.L Cash Flow Statement (2010 – 2022)
| 2022 | 2020 | 2019 | 2017 | 2015 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 120.9M | 227.4M | 80.3M | 61.2M | 45.94M | 30.49M | -6.70M | -15.52M |
Operating activities | ||||||||
Net income | 6.3M | 84M | 52.2M | 34.1M | 12.51M | 11.74M | 14.13M | 13.15M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 89.7M | 15.5M | 14.2M | 7.4M | 25.31M | 14.34M | 11.89M | 9.41M |
Stock-based compensation expense | -800K | 2.8M | 1.5M | 2.4M | 2.05M | 1.00M | 830K | 817K |
| Deferred income tax benefit | -800K | 2.8M | 1.5M | 2.4M | 2.05M | 1.00M | 830K | 817K |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | -21.5M | -19.7M | 6.9M | 0 | 0 | 0 | 0 | 0 |
Inventories | -31.1M | -36.6M | -15.7M | -22.5M | 11.78M | -4.84M | -4.81M | -3.12M |
Accounts payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | 63.6M | 89.1M | 106.4M | 64M | 43.57M | 19.24M | 16.75M | 17.32M |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -30.3M | -134.8M | -49.2M | -12.6M | -7.50M | -1.64M | -4.09M | -2.72M |
Acquisitions Net | -396.9M | -1.7M | -32.8M | -229.1M | -166.56M | -112.22M | -33.04M | 0 |
Cash generated by investing activities | -426.2M | -136.1M | -81.5M | -241.7M | -174.03M | -120.34M | -36.17M | -1.71M |
Financing activities | ||||||||
Common Stock Issued | 181.9M | 2.3M | 131.5M | 103.3M | 47.69M | 60.57M | 541K | 589K |
Payments for dividends | -51.7M | -37.9M | -33.3M | -21.8M | -15.29M | -8.32M | -7.22M | -6.19M |
Repurchases of common stock | -15.1M | 13.6M | 140.20M | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | -15.9M | 0 | 0 | 0 | -66.92M | -42.77M | -5.67M |
Cash used in financing activities | 316.5M | -55.1M | 118.9M | 193.8M | 125.31M | 103.70M | 18.86M | -10.82M |
Net Change In Cash | -46.5M | -109M | 147.1M | 18.5M | -6.80M | 1.93M | -27.39M | 8.82M |
Cash at end of period | 74.4M | 118.4M | 227.4M | 79.7M | 39.14M | 32.43M | -34.09M | -6.70M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |